Safety and antiviral activity of EGFR inhibition by erlotinib in chronic hepatitis C patients: a phase Ib randomized controlled trial.

Fiche publication


Date publication

avril 2022

Journal

Clinical and translational gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr HABERSETZER François, Dr LUPBERGER Joachim, Dr MUTTER Catherine


Tous les auteurs :
Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoël M, Schmidt-Mutter C, Baumert TF

Résumé

Significant hepatocellular carcinoma (HCC) risk persists following chronic hepatitis C (CHC) cure. Preclinical studies have shown that erlotinib, an oral EGFR inhibitor, has antiviral activity and HCC chemopreventive effect. Erlotinib is metabolized in the liver and its safety in patients with CHC is unknown. This study aimed to assess safety and antiviral activity of erlotinib in CHC patients.

Référence

Clin Transl Gastroenterol. 2022 Apr 1;: